Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: Stem Cells. 2014 Oct;32(10):2690–2701. doi: 10.1002/stem.1760

Figure 4. Blocking NKG2D increases survival of transplanted allogeneic NPCs.

Figure 4

Representative coronal spinal cord sections of the transplant site from JHMV-infected mice receiving either syngeneic eGFP-NPCs treated with IgG control antibody (A), allogeneic eGFP-NPCs plus anti-NKG2D (B) or IgG control antibody (C). Experimental mice were sacrificed at day 21 p.t. and migration/survival of transplanted cells was evaluated by visualization of eGFP-expression from transplanted cells. (D) Dual-positive DAPI and eGFP-NPCs were counted in coronal sections (9 mm rostral and 6 mm caudal to transplant site at 3 mm intervals) from mice syngeneically transplanted treated with an IgG control antibody (n=5), allogeneically transplanted treated with anti-NKG2D (n=5), and allogeneically transplanted treated with an IgG control antibody (n=4). Increased numbers of eGFP-NPCs (**p<0.01, ***p<0.001) were present within the spinal cords of allogeneically transplanted mice treated with anti-NKG2D antibody compared to allogeneically transplanted mice treated with an IgG control antibody. 100% (5/5) syngeneically transplanted mice treated with an IgG control antibody, 80% (4/5) allogeneically transplanted mice treated with anti-NKG2D, and 0% (0/4) allogeneically transplanted treated with an IgG control antibody had a surviving graft at day 21 p.t.